INmune Bio (INMB)
Develops innate-immunity therapies for rare disease, Alzheimer’s disease and cancer.
Something off on this page? Send us feedback.
Develops CORDStrom-derived Ebstrocel for RDEB, soluble-TNF inhibitor XPro for inflammation-selected Alzheimer’s disease, and NK-cell therapy INKmune for cancer. The clinical-stage pipeline operates as one segment and depends on licensed data and technology, external supply and manufacturing partners, regulatory approvals, and additional capital.
Develops therapies that modify innate-immune dysfunction across rare disease, neuroinflammation and cancer. CORDStrom-derived Ebstrocel, a pooled umbilical-cord stromal-cell candidate for RDEB, is the lead program and is moving toward planned UK, EU and US regulatory submissions.
XPro targets inflammation-selected early Alzheimer’s disease, while INKmune primes a patient’s natural-killer cells against residual cancer. Later XPro development requires a strategic partner, and INKmune is not being advanced under the current capital plan.
Operations span the United States and United Kingdom, with most employees based in the UK. The business relies on licensed MissionEB data and platform rights, third-party cord-tissue supply and manufacturing, regulatory acceptance, and continued financing. None of its named candidates is approved.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Mar 11, 2026 | LUCID CAPITAL MARKETS | Upgrade | ||
| Jul 1, 2025 | BTIG | Downgrade | ||
| Jul 1, 2025 | Scotiabank | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $18.4M · Total debt $1.4M · Total assets $26.8M · Shareholders' equity $20.4M
- Revenue
- $0
- Operating income
- −$1.5M
- Net income
- −$1.3M
No dividends on record.
| Institutions | 15.66% | 4.35M shares | |
|---|---|---|---|
| 87 holders · as of Jun 30, 2026 | |||
| Insiders | 10.45% | 2.90M shares | |
| 3 holders · as of Jul 7, 2026 | |||
| Strategic holders | 5.24% | 1.45M shares | |
| 1 holder · as of Aug 14, 2025 | |||
| Other | 68.65% | 19.05M shares | |
| remainder | |||
27.75M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Mark William LowdellInsiderofficer: Chief Scientific Officer | 5.47% | 1.52M | filed Jul 7, 2026 |
Highbridge Capital Management, LLCStrategic | 5.24% | 1.45M | filed Aug 14, 2025 |
David J. MossInsiderdirector, officer: Chief Executive Officer | 4.67% | 1.29M | filed Jul 7, 2026 |
Vanguard Capital Management LLCInstitution | 2.55% | 706,424 | as of Jun 30, 2026 |
AQR Capital Management LLCInstitution | 2.39% | 662,218 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Krystal Biotech
Commercial DEB gene therapy with recurring topical wound care
- Abeona Therapeutics
Autologous cell-sheet gene therapy for RDEB wounds
- Eli Lilly
Approved anti-amyloid therapy for overlapping early Alzheimer’s patients
- Biogen
LEQEMBI co-commercializer with a broad early Alzheimer’s pipeline
- BioVie
TNF-linked neuroinflammation program closest to XPro’s mechanism
- GT Biopharma
NK-cell engager in prostate and other solid tumors
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| INmune Bio | $2.03 | −6.25% | $57.4M | — | — | — | — |
| Krystal Biotech | $338.76 | −3.45% | $10.34B | 44.0 | 39.9 | 23.5 | +24.1% |
| Abeona Therapeutics | $5.56 | −4.55% | $331.7M | — | — | 13.0 | +2,745.0% |
| Eli Lilly | $1,152.13 | −1.54% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Biogen | $223.12 | −1.00% | $33.30B | 39.9 | 16.8 | 3.3 | +3.4% |
| BioVie | $1.64 | +0.61% | $12.3M | — | — | — | — |
| GT Biopharma | $7.12 | −0.84% | $9.1M | — | — | — | — |
| Median | 39.9 | 28.2 | 13.4 | +35.9% |